Schrodinger, Inc. - SDGR STOCK NEWS

Schrödinger (SDGR) presented new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, at the 36th EORTC-NCI-AACR Symposium. The data shows SGR-3515 achieves superior anti-tumor activity through dual inhibition of Wee1 and Myt1, with a favorable pharmacological profile supporting intermittent dosing. A Phase 1 dose-escalation study is ongoing with initial data expected in H2 2025. The company also presented data on its PRMT5-MTA inhibitor program, showcasing a novel series of selective compounds for peripheral and brain tumors.

Schrödinger (Nasdaq: SDGR) announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and the company’s PRMT5-MTA inhibitor program will be presented at the 36th EORTC-NCI-AACR Symposium (ENA 2024) from October 23-25, 2024, in Barcelona, Spain.

The SGR-3515 presentation will highlight data characterizing SGR-3515 in preclinical oncology models, showing its potential as a therapy for advanced solid tumors. A Phase 1 clinical trial is ongoing. The PRMT5-MTA presentation will cover the discovery of a novel series of selective, potent PRMT5-MTA inhibitors optimized for peripheral and brain tumors.

Details of the presentations include:

• SGR-3515: October 23, 2024, 12PM-2PM CEST, Abstract Number: 147
• PRMT5-MTA: October 25, 2024, 9AM-3PM CEST, Abstract Number: 372

Schrödinger (Nasdaq: SDGR), a company revolutionizing drug and materials discovery through physics-based computational methods, has announced the granting of restricted stock units (RSUs) to eight new employees on September 13, 2024. The grants, totaling 7,025 shares of common stock, were approved under the company's 2021 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). These RSUs are designed to vest over four years, with 25% vesting after the first year of continuous service and the remaining 75% vesting in equal yearly installments over the following three years. This move serves as a material inducement for the new hires, aligning their interests with the company's long-term success.

Schrödinger (Nasdaq: SDGR), a company revolutionizing therapeutics and materials discovery through physics-based computational platforms, has announced the granting of restricted stock units (RSUs) to 13 new employees. On August 14, 2024, the company awarded a total of 7,500 RSUs as part of its 2021 Inducement Equity Incentive Plan. These grants, approved by the compensation committee, serve as a material inducement for employment in compliance with Nasdaq Listing Rule 5635(c)(4).

The RSUs have a four-year vesting schedule, with 25% vesting after 12 months of continuous service, followed by equal yearly installments over the subsequent three years. This move aligns with Schrödinger's strategy to attract and retain top talent in the competitive field of computational drug and materials discovery.

Schrödinger (SDGR), a company revolutionizing drug and materials discovery with its physics-based computational platform, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, September 4, 2024, at 3:20 p.m. ET.

Investors and interested parties can access the live webcast of the presentation through the 'Investors' section of Schrödinger's website. The recorded session will remain available for approximately 90 days after the event, providing an extended opportunity for those unable to attend the live presentation to gain insights into the company's developments and strategies.

Schrödinger (Nasdaq: SDGR) reported strong Q2 2024 financial results with total revenue of $47.3 million, a 35% increase year-over-year. Software revenue grew 21% to $35.4 million, while drug discovery revenue more than doubled to $11.9 million. The company launched a major initiative to expand its computational tools for predictive toxicology, funded by a $10 million grant from the Bill & Melinda Gates Foundation. Schrödinger expects to report initial clinical data for its lead programs SGR-1505 in 1H25, and SGR-2921 and SGR-3515 in 2H25. The company updated its 2024 financial outlook, maintaining software revenue growth guidance of 6-13% and drug discovery revenue expectations of $30-35 million.

Schrödinger (NASDAQ: SDGR) has launched an initiative to expand its computational platform for predictive toxicology in drug discovery. The project aims to develop tools to improve drug candidates' properties and reduce development failures due to off-target protein binding. Funded by a $10 million grant from the Bill & Melinda Gates Foundation, the initiative will leverage Schrödinger's physics-based platform and NVIDIA's AI technologies.

The resulting technology will be available to Gates Foundation grantees, Schrödinger's software customers, and for the company's drug discovery programs. This initiative addresses a significant challenge in drug development, as safety issues are a frequent cause of delays and failures. The project aligns with the FDA's Predictive Toxicology Roadmap and has the potential to accelerate drug discovery while reducing toxicity risks in preclinical and clinical studies.

Schrödinger (Nasdaq: SDGR), a company revolutionizing therapeutics and materials discovery with its physics-based computational platform, has announced it will release its second quarter 2024 financial results on Wednesday, July 31, 2024, after the financial markets close. The company will follow this with a conference call and webcast at 4:30 p.m. ET on the same day.

Investors and interested parties can access the live webcast through the 'Investors' section of Schrödinger's website. The webcast will remain archived on the site for approximately 90 days after the event, allowing for later viewing.

Schrödinger (Nasdaq: SDGR), a company using physics-based computational platforms for drug and materials discovery, has reported granting restricted stock units (RSUs) to eight new employees. The grants, totaling 9,990 shares of common stock, were made on July 12, 2024, under the company's 2021 Inducement Equity Incentive Plan.

These RSUs are part of the employees' compensation packages and were approved as a material inducement for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs have a four-year vesting schedule, with 25% vesting after 12 months of continuous service and the remaining 75% vesting in equal yearly installments over the following three years.